Posts

The endocannabinoidome as a substrate for noneuphoric phytocannabinoid action and gut microbiome dysfunction in neuropsychiatric disorders

Authors: Vincenzo Di Marzo, PhD Published in DIALOGUES IN CLINICAL NEUROSCIENCE 2020 Abstract The endocannabinoid (eCB) system encompasses the eCBs anandamide and 2-arachidonoylglycerol, their anabolic/catabolic enzymes, and the cannabinoid CB1 and CB2 receptors. Its expansion to include several eCB-like lipid mediators, their metabolic enzymes, and their molecular targets, forms the endocannabinoidome (eCBome). This complex signaling…

The present status of artisanal cannabis for the treatment of epilepsy in the United States.

Authors: Dustin Sulak, Russell Saneto, Bonni Goldstein Published in Epilepsy & Behavior May 2017 Abstract The widespread patient use of artisanal cannabis preparations has preceded quality validation of cannabis use for epilepsy. Neurologists and cannabinoid specialists are increasingly in a position to monitor and guide the use of herbal cannabis in epilepsy patients. We report…

Cannabidiol upregulates melanogenesis through CB1 dependent pathway by activating p38 MAPK and p42/44 MAPK

Authors: Young Sun Hwang, Youn-Jung Kim, Mi Ok Kim, Mingyeong Kang, Sae Woong Oh, Youn Hwa Nho, See-Hyoung Park, Jongsung Lee Published in Science Direct August 2017 Abstract Melanogenesis plays a critical role in the protection of skin against external stresses such as ultraviolet irradiation and oxidative stressors. This study was aimed to investigate the…

Evaluation of the effects of CBD hemp extract on opioid use and quality of life indicators in chronic pain patients: a prospective cohort study

Author: Alex Capano, Richard Weaver & Elisa Burkman Published in Postgraduate Medicine   November 2019 Abstract Context: Chronic pain is highly prevalent in most of the industrialized nations around the world. Despite the documented adverse effects, opioids are widely used for pain management. Cannabinoids, and specifically Cannabidiol, is proposed as an opioid alternative, having comparable efficacy…

Δ9‐Tetrahydrocannabinolic acid alleviates collagen‐induced arthritis: Role of PPARγ and CB1 receptors

Authors: Belén Palomares, Martín Garrido‐Rodriguez, Claudia Gonzalo‐Consuegra, María Gómez‐Cañas, Suwipa Saen‐oon, Robert Soliva, Juan A. Collado, Javier Fernández‐Ruiz, Gaetano Morello, Marco A. Calzado, Giovanni Appendino, Eduardo Muñoz Published in British Journal of Pharmacology  June 2020 Abstract Background and Purpose: Δ9‐Tetrahydrocannabinolic acid (Δ9‐THCA‐A), the precursor of Δ9‐THC, is a non‐psychotropic phytocannabinoid that shows PPARγ agonist activity. Here,…

The synthetic cannabinoid WIN55212‐2 decreases the intraocular pressure in human glaucoma resistant to conventional therapies

Author: Anna Porcella Chiara Maxia Gian Luigi Gessa Luca Pani Published in European Journal of Neuroscience March 1980 Abstract The search for new ocular hypotensive agents represents a frontier of current eye research because blindness due to optic neuropathy occurs insidiously in 10% of all patients affected by glaucoma. Cannabinoids have been proposed to lower intraocular…

Changes in endocannabinoid and palmitoylethanolamide levels in eye tissues of patients with diabetic retinopathy and age-related macular degeneration

Author: I. Matias, J.W. Wang, A. Schiano Moriello, A. Nieves, D.F. Woodward,V. Di Marzo Published in Science Direct December 2006 Abstract Cannabinoid receptors and the endocannabinoids (anandamide (N-arachidonoylethanolamine—AEA) and 2-arachidonoylglycerol (2-AG)), as well as the AEA congener, palmitoylethanolamide (PEA), are involved in ocular physiology. We measured endocannabinoid and PEA levels by isotope-dilution liquid chromatography-mass spectrometric analysis…

Finding of endocannabinoids in human eye tissues: Implications for glaucoma

Author: June Chen, Isabel Matias, Tim Dinh, Ta Lu, Sonia Venezia, Amelia Nieves, David F. Woodward, Vincenzo Di Marzo Published in Science Direct May 2005 Abstract Cannabinoid CB1 receptors are involved in ocular physiology and may regulate intraocular pressure (IOP). However, endocannabinoid levels in human ocular tissues of cornea, iris, ciliary body, retina, and choroid from…

Δ9‐Tetrahydrocannabinolic acid alleviates collagen‐induced arthritis: Role of PPARγ and CB1 receptors

Author: Belén Palomares Martín Garrido‐Rodriguez Claudia Gonzalo‐Consuegra María Gómez‐Cañas Suwipa Saen‐oon Robert Soliva Juan A. Collado Javier Fernández‐Ruiz Gaetano Morello Marco A. Calzado Giovanni Appendino Eduardo Muñoz Published in British Pharmacological Society  June 2020 Abstract Background and Purpose Δ9‐Tetrahydrocannabinolic acid (Δ9‐THCA‐A), the precursor of Δ9‐THC, is a non‐psychotropic phytocannabinoid that shows PPARγ agonist activity. Here, we investigated…

Colon carcinogenesis is inhibited by the TRPM8 antagonist cannabigerol, a Cannabis-derived non-psychotropic cannabinoid

Authors: Francesca Borrelli, Ester Pagano, Barbara Romano, Stefania Panzera, Francesco Maiello, Diana Coppola, Luciano De Petrocellis, Lorena Buono, Pierangelo Orlando, Angelo A. Izzo Published in Oxford Academic September 2014 Abstract Cannabigerol (CBG) is a safe non-psychotropic Cannabis-derived cannabinoid (CB), which interacts with specific targets involved in carcinogenesis. Specifically, CBG potently blocks transient receptor potential (TRP) M8…

Cannabinoid Hyperemesis Syndrome: A Review of Potential Mechanisms

Authors: Marieka V. DeVuono, Linda A. Parker Published in Mary Ann Liebert, Inc Publishers June 2020 Abstract Introduction Cannabinoids have long been known for their ability to treat nausea and vomiting. Recent reports, however, have highlighted the paradoxical proemetic effects of cannabinoids. Cannabinoid hyperemesis syndrome (CHS) is characterized by cyclical episodes of nausea and vomiting, accompanied…